Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
Adagene (Nasdaq: ADAG) has announced an upcoming poster presentation at the ASCO 2025 Annual Meeting in Chicago. The presentation will focus on their masked anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) therapy. The poster will showcase updated results from a Phase 1b/2 study examining the safety and efficacy of ADG126 in combination with Pembrolizumab for advanced MSS CRC treatment.
The presentation is scheduled for Saturday, May 31, 2025, with poster viewing from 9:00 AM to 12:00 PM CDT at McCormick Place, Chicago (Board #248, Abstract #3579). The poster will be accessible on the company's website Publications page.
Adagene (Nasdaq: ADAG) ha annunciato una prossima presentazione poster al ASCO 2025 Annual Meeting a Chicago. La presentazione sarà incentrata sulla loro terapia SAFEbody® anti-CTLA-4 mascherata ADG126 (Muzastotug). Il poster mostrerà i risultati aggiornati di uno studio di Fase 1b/2 che esamina la sicurezza e l'efficacia di ADG126 in combinazione con Pembrolizumab per il trattamento del CRC MSS avanzato.
La presentazione è prevista per sabato 31 maggio 2025, con esposizione del poster dalle 9:00 alle 12:00 CDT presso il McCormick Place di Chicago (Board #248, Abstract #3579). Il poster sarà disponibile sulla pagina Pubblicazioni del sito web dell'azienda.
Adagene (Nasdaq: ADAG) ha anunciado una próxima presentación en formato póster en la Reunión Anual ASCO 2025 en Chicago. La presentación se centrará en su terapia SAFEbody® anti-CTLA-4 enmascarada ADG126 (Muzastotug). El póster mostrará resultados actualizados de un estudio de Fase 1b/2 que evalúa la seguridad y eficacia de ADG126 en combinación con Pembrolizumab para el tratamiento del CRC MSS avanzado.
La presentación está programada para el sábado 31 de mayo de 2025, con visualización del póster de 9:00 a 12:00 CDT en McCormick Place, Chicago (Board #248, Abstract #3579). El póster estará disponible en la página de Publicaciones del sitio web de la compañía.
Adagene (나스닥: ADAG)는 시카고에서 열리는 ASCO 2025 연례회의에서 포스터 발표를 예정하고 있다고 발표했습니다. 이번 발표는 마스킹된 항-CTLA-4 SAFEbody® 치료제 ADG126(뮤자스토투그)에 초점을 맞출 예정입니다. 포스터에는 진행성 MSS CRC 치료를 위한 펨브롤리주맙과 병용한 ADG126의 안전성과 효능을 평가한 1b/2상 연구의 최신 결과가 포함됩니다.
발표는 2025년 5월 31일 토요일로 예정되어 있으며, 오전 9시부터 12시까지 CDT 시간 기준으로 시카고 맥코믹 플레이스에서 포스터를 관람할 수 있습니다(보드 #248, 초록 #3579). 포스터는 회사 웹사이트의 출판물 페이지에서 확인할 수 있습니다.
Adagene (Nasdaq : ADAG) a annoncé une prochaine présentation sous forme de poster lors de la réunion annuelle ASCO 2025 à Chicago. La présentation portera sur leur thérapie SAFEbody® anti-CTLA-4 masquée ADG126 (Muzastotug). Le poster présentera les résultats mis à jour d'une étude de phase 1b/2 examinant la sécurité et l'efficacité d'ADG126 en association avec le Pembrolizumab pour le traitement du CRC MSS avancé.
La présentation est prévue pour le samedi 31 mai 2025, avec une consultation du poster de 9h00 à 12h00 CDT au McCormick Place de Chicago (Board #248, Résumé #3579). Le poster sera accessible sur la page Publications du site web de l'entreprise.
Adagene (Nasdaq: ADAG) hat eine bevorstehende Posterpräsentation auf dem ASCO 2025 Jahrestreffen in Chicago angekündigt. Die Präsentation wird sich auf ihre maskierte anti-CTLA-4 SAFEbody® Therapie ADG126 (Muzastotug) konzentrieren. Das Poster zeigt aktualisierte Ergebnisse einer Phase 1b/2 Studie zur Sicherheit und Wirksamkeit von ADG126 in Kombination mit Pembrolizumab zur Behandlung von fortgeschrittenem MSS CRC.
Die Präsentation ist für Samstag, den 31. Mai 2025, geplant, mit Posterbesichtigung von 9:00 bis 12:00 Uhr CDT im McCormick Place, Chicago (Board #248, Abstract #3579). Das Poster wird auf der Publikationsseite der Firmenwebseite zugänglich sein.
- None.
- None.
SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.
- Abstract Title: Safety and Efficacy of ADG126 (an Anti-CTLA-4 Masking Antibody) in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRC
- Date: Saturday, May 31, 2025
- Poster Viewing: 9:00 AM-12:00 PM CDT
- Onsite Location: McCormick Place, Chicago, IL, Board #248
- Abstract Number: 3579
Poster will be made available on the Publications page of the company’s website here.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com
FAQ
What will Adagene (ADAG) present at ASCO 2025?
When and where is Adagene's (ADAG) ASCO 2025 poster presentation?
What is ADG126 and what is it being studied for?
Where can investors find Adagene's (ADAG) ASCO 2025 poster after the presentation?
